Advertisement


Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Deborah Collyar: What's In It for Patients?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement



Aug
09
Today In Oncology
Increased Utilization of SBRT Has Decreased Treatment Disparities for Early-Stage NSCLC
Study Finds Adding Tremelimumab and Durvalumab to Chemotherapy Improves Overall Survival in Metastatic NSCLC Regardless of KRAS/STK11/KEAP1 Mutations
Addition of Transarterial Chemoembolization to Lenvatinib in First-Line Treatment of Advanced Hepatocellular Carcinoma
An Early Encounter With Cancer Sets a Path to a Career in Oncology Research
Long-Term Regional Disease Control With Sentinel Lymph Node Biopsy in Patients With Melanoma
View More 
Advertisement
© 2022 HSP News Service, L.L.C.
Designed by Harborside